124 related articles for article (PubMed ID: 35970135)
21. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
22. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
23. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
[TBL] [Abstract][Full Text] [Related]
24. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
25. Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion.
Ojasalu K; Brehm C; Hartung K; Nischak M; Finkernagel F; Rexin P; Nist A; Pavlakis E; Stiewe T; Jansen JM; Wagner U; Gattenlöhner S; Bräuninger A; Müller-Brüsselbach S; Reinartz S; Müller R
Mol Oncol; 2020 Sep; 14(9):2142-2162. PubMed ID: 32533757
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival.
Williams E; Martin S; Moss R; Durrant L; Deen S
Virchows Arch; 2012 Jul; 461(1):33-9. PubMed ID: 22699808
[TBL] [Abstract][Full Text] [Related]
27. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
28. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract][Full Text] [Related]
29. Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
De Haven Brandon A; Box G; Hallsworth A; Court W; Matthews N; Herodek B; Arteagabeitia AB; Valenti M; Kirkin V
Sci Rep; 2020 Jul; 10(1):10799. PubMed ID: 32612269
[TBL] [Abstract][Full Text] [Related]
30. Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.
Kobayashi H; Ogawa K; Kawahara N; Iwai K; Niiro E; Morioka S; Yamada Y
Free Radic Res; 2017 Oct; 51(9-10):755-764. PubMed ID: 28931330
[TBL] [Abstract][Full Text] [Related]
31. Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines.
Varankar SS; More M; Abraham A; Pansare K; Kumar B; Narayanan NJ; Jolly MK; Mali AM; Bapat SA
Carcinogenesis; 2020 Jun; 41(4):515-526. PubMed ID: 31241128
[TBL] [Abstract][Full Text] [Related]
32. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
33. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
[TBL] [Abstract][Full Text] [Related]
34. HNF-1β in ovarian carcinomas with serous and clear cell change.
DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
[TBL] [Abstract][Full Text] [Related]
35. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
36. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
[TBL] [Abstract][Full Text] [Related]
37. Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.
Darb-Esfahani S; Kolaschinski I; Trillsch F; Mahner S; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Wienert S; Taube ET; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
Histopathology; 2018 Dec; 73(6):1002-1012. PubMed ID: 30007074
[TBL] [Abstract][Full Text] [Related]
38. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
39. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
[TBL] [Abstract][Full Text] [Related]
40.
Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]